TOBINintel · Condition

Obesity & Metabolic Dysfunction

Obesity is modeled as a disorder of energy signaling rather than a BMI value: endocrine-active exposures, mitochondrial and redox function, insulin, leptin, thyroid and sex-hormone signaling, adipose inflammation, microbiome relationships and nutrient adequacy are each evaluated separately.

Key points

Bacteriome shifts and SCFA production are evaluated as a dysbiosis hypothesis, not an infection. Antimicrobials are not indicated on the basis of a microbiome pattern alone.
Test to discuss: Body composition and waist circumference
Test to discuss: Fasting glucose, insulin, HbA1c, HOMA-IR
Test to discuss: Lipid panel with ApoB and Lp(a)
Test to discuss: Liver enzymes and hepatic imaging where indicated
Test to discuss: Thyroid studies and sex hormones when clinically justified
Reduce ultra-processed food share
Protein and fiber adequacy at each meal
Sleep regularity and 7–9 hours
Reduce avoidable endocrine-active exposures
Resistance training twice weekly

Root-cause chain

Endocrine-active chemical exposure → Receptor and signaling interactionD

T · Mechanistic plausibility · In-vitro and animal work shows nuclear-receptor binding and altered transcription of adipogenic genes. Human exposure data come from population biomonitoring; detection alone does not establish an effect.

Altered insulin and leptin signaling → Adipocyte dysfunctionB

B · Observational association · Cohort data link hyperinsulinemia and leptin resistance to adipocyte hypertrophy and impaired lipolysis; interventional data are narrower.

Visceral adipose inflammation → Insulin resistanceA

I · Established causal · Macrophage infiltration and cytokine release impair insulin receptor substrate signaling; consistently reproduced across human and animal evidence.

Ultra-processed dietary pattern → Excess energy intake and weight gainA

N · Randomized evidence · Controlled feeding trials show higher ad-libitum energy intake and weight gain on ultra-processed diets at matched macronutrients.

Protocols by lane

Evidence grade + regulatory status

Conventional: GLP-1 receptor agonist therapyA

Reduces weight and cardiometabolic events in guideline-eligible patients.

Status: FDA-approved · Cautions: Contraindicated with personal/family medullary thyroid carcinoma or MEN2; monitor GI tolerance, gallbladder and pancreatitis signals.

Functional: Structured sleep and circadian correctionB

Short and irregular sleep worsens insulin sensitivity and appetite regulation.

Status: Lifestyle · Cautions: Screen for obstructive sleep apnea before attributing fatigue to habits.

Integrative: Supervised resistance plus aerobic trainingA

Improves insulin sensitivity and preserves lean mass during weight loss.

Status: Lifestyle · Cautions: Cardiac clearance where symptoms or risk factors are present.

Orthomolecular: Vitamin D repletion when deficientC

Corrects a measured deficiency; not a weight-loss intervention on its own.

Status: Supplement · Cautions: Dose to measured 25-OH vitamin D; caution in hypercalcemia, sarcoidosis and thiazide use.

Traditional: Traditional whole-food dietary pattern (e.g. Mediterranean)A

Consistent cardiometabolic benefit across trials and cohorts.

Status: Lifestyle · Cautions: Adapt to allergy, renal and cultural context.

Energy / Physical: Photobiomodulation as adjunct for recoveryD

Limited preliminary evidence for muscle recovery; no evidence for fat loss.

Status: Investigational · Cautions: Must not be presented as a treatment for obesity or metabolic disease.

Monitoring

Weight and waist trend every 30 days
HbA1c and lipids at 90 and 180 days
Medication review at each visit
TOBIN score change over time

Go deeper

Full condition page →Library: formulas & sources →All TOBINintel entries

iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.